Pablo Shimaoka Chagas

9PUBLICATIONS
28CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Epigenetics (incl. genome methylation and epigenomics)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 09, 2026
Therapeutic Potential of Targeting USP2 in Pediatric Group 3 and 4 Medulloblastomas: Insights from In Silico, Ex Vivo, and In Vitro Studies.

|Nov 27, 2024
SIGMAR1 Knockdown Enhances Oral Cancer Cell Chemosensitivity to Cisplatin via Decreased PD-L1 Expression.

Pablo Shimaoka Chagas, Cristiana Bernadelli Garcia, Lucas Oliveira Sousa

|Jun 26, 2024
Network-Based Transcriptome Analysis Reveals FAM3C as a Novel Potential Biomarker for Glioblastoma.

Pablo Shimaoka Chagas, Henrique Izumi Shimaoka Chagas, Sahar Emami Naeini

|Dec 22, 2023
SET protein as an epigenetics target.

Gabriel da Silva, Thaís Moré Milan, Pablo Shimaoka Chagas

|Jul 17, 2023
Musashi-1 regulates cell cycle and confers resistance to cisplatin treatment in Group 3/4 medulloblastomas cells.

Pablo Shimaoka Chagas, Luciana Chain Veronez, Graziella Ribeiro de Sousa

|Dec 24, 2021
YAP1 Is a Potential Predictive Molecular Biomarker for Response to SMO Inhibitor in Medulloblastoma Cells.

Gustavo Alencastro Veiga Cruzeiro, Taciani de Almeida Magalhães, Graziella Ribeiro de Sousa

Pageof 2

Frequent Collaborators

3 joint publications

Carlos Alberto Scrideli

3 joint publications

Luiz Gonzaga Tone

3 joint publications

Elvis Terci Valera

2 joint publications

Andréia Machado Leopoldino